TD Cowen analyst Ken Cacciatore lowered the firm’s price target on Biohaven (BHVN) to $15 from $50 and keeps a Buy rating on the shares. The firm said the CRL for Vyglxia is highly disappointing, and they are unsure if it will ever make it to market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- 3 Best Stocks to Buy Now, 11/5/2025, According to Top Analysts
- FDA complete response letter cites issues in Biohaven Vyglxia NDA
- Biohaven Ltd.: Navigating Setbacks with Strategic Restructuring and Promising Pipeline
- Strategic Realignment and Pipeline Potential Drive Buy Rating for Biohaven Ltd.
- Video: What is dragging down Biohaven today